Literature DB >> 18536889

Lipodystrophy in pediatric HIV.

Ninad Desai1, Patricia Mullen, Mudit Mathur.   

Abstract

OBJECTIVE: To assess fat accumulation in children with HIV/AIDS on long term HAART using CDC defined Body mass Index (BMI) criteria and measured Bioelectric Impedance (BI).
METHODS: Prospective study of 48 HIV infected children (ages 6-15 years) on HAART to determine the incidence of lipodystrophy and evaluate methods of determining body fat accumulation. Lipodystrophy was diagnosed using clinical features-truncal obesity with facial/limb wasting. BMI (weight in kg/height in meters2) was plotted on CDC curves to predict the risk of obesity. BI was performed using Omron's HBF301 body fat analyzer and reported as TBF %/height. Serum cholesterol and triglycerides were measured. Results were compared using ANOVA
RESULTS: Average duration of HAART was 2.4 years. Forty five of 48 patients were on protease inhibitors. Fifteen (31%) developed Lipodystrophy, but CDC BMI curves identify only 7/15 as overweight or at risk for obesity. However, TBF/Ht of 30% (using BI) was 85% sensitive and 88% specific in identifying Lipodystrophy. Hyperlipidemia occurred in 28/48 (58%) overall, in 14/15 (93%) diagnosed with lipodystrophy.
CONCLUSION: Lipodystrophy is a significant problem in children with HIV/AIDS on HAART. BI is more useful than BMI in identifying patients with abnormal fat accumulation and should be incorporated in their routine assessment in the ambulatory setting.

Entities:  

Mesh:

Year:  2008        PMID: 18536889     DOI: 10.1007/s12098-008-0037-2

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  9 in total

1.  Comparison of a footpad analyser with a tetrapolar model for the determination of percent body fat in young men.

Authors:  C E Spencer; J M Lingard; M A Bermingham
Journal:  J Sci Med Sport       Date:  2003-12       Impact factor: 4.319

Review 2.  [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings].

Authors:  Sandra Lassalle; Pascale Cervera; Véronique Hofman; Mireille Mari; Pierre Dellamonica; Paul Hofman
Journal:  Ann Pathol       Date:  2005-09       Impact factor: 0.407

3.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; O Rouviere; F Bruno; R Avellaneda; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

Review 4.  Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.

Authors:  Giuseppe Barbaro
Journal:  Curr HIV Res       Date:  2006-01       Impact factor: 1.581

5.  Body mass index as a measure of adiposity among children and adolescents: a validation study.

Authors:  A Pietrobelli; M S Faith; D B Allison; D Gallagher; G Chiumello; S B Heymsfield
Journal:  J Pediatr       Date:  1998-02       Impact factor: 4.406

Review 6.  HIV protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

7.  A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals.

Authors:  R Power; H L Tate; S M McGill; C Taylor
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

8.  Body composition in patients with acquired immunodeficiency syndrome: a validation study of bioelectric impedance analysis.

Authors:  T E Sluys; M E van der Ende; G R Swart; J W van den Berg; J H Wilson
Journal:  JPEN J Parenter Enteral Nutr       Date:  1993 Sep-Oct       Impact factor: 4.016

9.  Body mass index in screening for adiposity in children and adolescents: systematic evaluation using receiver operating characteristic curves.

Authors:  R Lazarus; L Baur; K Webb; F Blyth
Journal:  Am J Clin Nutr       Date:  1996-04       Impact factor: 7.045

  9 in total
  6 in total

1.  Endocrinopathies in HIV, AIDS and HAART.

Authors:  Amrit Bhangoo; Ninad Desai
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 2.  Of mice and monkeys: can animal models be utilized to study neurological consequences of pediatric HIV-1 infection?

Authors:  Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke
Journal:  ACS Chem Neurosci       Date:  2015-06-19       Impact factor: 4.418

Review 3.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 4.  HIV protease inhibitors and obesity.

Authors:  Erdembileg Anuurad; Andrew Bremer; Lars Berglund
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-10       Impact factor: 3.243

5.  Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.

Authors:  Euden Bhutia; Alok Hemal; Tribhuvan Pal Yadav; K L Ramesh
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

Review 6.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.